We are very excited by MariTides differentiated profile, with clinically meaningful attributes of substantial and progressive weight loss, monthly or less frequent dosing, significant improvements in cardiometabolic parameters and strong reduction of HbA1c, said Jay Bradner, MD, executive vice president of Research and Development and chief scientific officer at Amgen in a press release announcing the trial data
Here, we review the role of GLP-1 and the actions of associated therapies on glucose metabolism, the gutrenal axis, classical renal risk factors, and renal end points in randomized controlled trials of GLP-1 receptor agonists and DPP-4 inhibitors in patients with T2DM
Understanding the pharmacological mechanism of Ozempic helps explain why gastrointestinal side effects, including potentially sulfur burps, occur in some patients
Stability allows 12 months unopened storage at 2-8C and 60 days post-reconstitution